South Africa to Manufacture Twice-Yearly HIV Prevention Drug
A South African laboratory is set to produce a generic version of lenacapavir, a revolutionary twice-yearly HIV injection, marking a significant milestone in Africa’s push toward pharmaceutical self-sufficiency, global health agency Unitaid announced on Tuesday. Lenacapavir, originally developed by American pharmaceutical giant Gilead Sciences, has drawn widespread medical attention for its exceptional efficacy….
